Taste and smell disturbances in patients with gastrointestinal stromal tumors using tyrosine-kinase inhibitors.
- Conditions
- Gastro-intestinal stromal tumors
- Registration Number
- NL-OMON21230
- Lead Sponsor
- niversity Medical Center Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 50
Inclusion Criteria
Pathologically confirmed diagnosis of a GIST
-Currently treated with imatinib, sunitinib or regorafenib
-Able to understand spoken and written Dutch
-Ability to comprehend and complete questionnaire by phone
-> 18 years
Exclusion Criteria
-No oral food intake
-Coexisting-morbidities affecting taste or smell function
-Uncertainty about the willingness or ability of the patient to comply with the protocol requirements
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method What is the prevalence of taste and smell disturbances in GIST patients using TKIs?
- Secondary Outcome Measures
Name Time Method What is the type of taste and smell disturbances in GIST patients using TKIs?<br>What is the association between taste and smell disturbances and impact on daily life and QoL?<br>What are the differences between imatinib, sunitinib and regorafenib in taste and smell disturbances?<br>What is the association between taste and smell disturbances and the duration of the TKI use?